If it wasn't obvious before, Latigo Biotherapeutics is all in on its non-opioid pain treatment pipeline and that is highlighted further by the company's $150 million Series B capital raise. Announced ...

We are the Artful Dodgers of the globalised world, experts at ducking and diving - but even the Dodger gets caught in the end ...